Temporal trends in new and recurrent oesophageal strictures in a Medicare population

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 10, 2007, Pages 1223-1229

  El Serag, H B ^a,b   Lau, M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CONTROLLED STUDY; ENDOSCOPY; ESOPHAGUS DILATATION; ESOPHAGUS STRICTURE; FEMALE; HUMAN; INCIDENCE; MALE; MEDICARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK REDUCTION;

AGED; AGED, 80 AND OVER; ESOPHAGEAL STENOSIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MEDICARE; MIDDLE AGED; PROTON PUMPS; RECURRENCE;

EID: 34247465217     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03310.x     Document Type: Article

References (15)

1. Barbezat GO, Schlup M, Lubcke R. Omeprazole therapy decreases the need for dilatation of peptic oesophageal strictures. Aliment Pharmacol Ther 1999 13 : 1041 5.
2. Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994 106 : 907 715.
3. Kawano S, Murata H, Tsuji S, et al. Randomized comparative study of omeprazole and famotidine in reflux esophagitis. J Gastroenterol Hepatol 2002 17 : 955 9.
4. Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology 1994 107 : 1312 8.
5. Nayyar AK, Royston C, Bardhan KD. Oesophageal acid-peptic strictures in the histamine H2 receptor antagonist and proton pump inhibitor era. Dig Liver Dis 2003 35 : 143 50.
6. Guda NM, Vakil N. Proton pump inhibitors and the time trends for esophageal dilation. Am J Gastroenterol 2004 99 : 797 800.
7. El- Serag HB. Temporal trends in new and recurrent esophageal strictures in Department of Veterans Affairs. Am J Gastroenterol 2006 101 : 1727 33.
8. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika 1981 68 : 373 9.
9. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005 54 : 710 7.
10. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005 97 : 142 6.
11. Pace F, Bianchi Porro G. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol 2004 99 : 946 9.
12. Fass R, Ofman JJ. Gastroesophageal reflux disease - should we adopt a new conceptual framework Am J Gastroenterol 2002 97 : 1901 9.
13. El- Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004 99 : 1877 83.
14. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004 180 : 387 91.
15. van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005 54 : 1062 6.